Description

Visionary senior executive with a track record of transforming organisations, driving commercial success, and leading global business strategies in cardiometabolic/renal, autoimmune diseases, oncology and hematology markets.

Proven ability to deliver above-market growth, scale global franchises, and manage multi billion-dollar portfolios with full P&L accountability. Adept at launching blockbuster therapies,

navigating complex market ecosystems, and leading high-performing team.

Expert in general management and commercial strategy, global franchise leadership, lifecycle management and ecosystem transformation, cross-functional leadership and talent development, P&L management and business growth.

Industry field of expertise

Languages

German
Native or bilingual
English
Native or bilingual
French
Conversational

Workplace preferences

Can work on-site

Zürich (up to 50km)

Novo Nordisk A/S
Interim Corporate Vice President, Diabetes Commercial Unit
May 2022 - August 2022 (3 months)
Denmark
Led global diabetes business unit, overseeing 5 Vice Presidents and defining strategy for GLP-1 and insulin portfolios

Drove market expansion strategies and prepared for first weekly insulin launch
Product Launch Strategy New product launch Change and Transformation Management Global Marketing Portfolio Strategy
Novo Nordisk A/S
Project Vice President Global Commercial - Oral Semaglutide
PHARMACEUTICALS INDUSTRY
October 2021 - April 2025 (3 years and 6 months)
Denmark
Leading Global Project Team for Oral Semaglutide, focusing on long-term life cycle strategy and P&L accountability

Managing cross-functional teams of 15+ senior leaders and oversee multi-million dollar budgets to expand market leadership

Spearhead global ecosystem strategies, shaping treatment goals, drug development, supply chain and commercialisation
Ecosystem Development Product Launch Strategy Global Marketing Growth Strategies Supply-Chain Management
Novo Nordisk A/S
VP Global Marketing Ozempic & Victoza
PHARMACEUTICALS INDUSTRY
March 2020 - January 2021 (10 months)
Denmark
Strategic lead of the injectable GLP-1 franchise, achieving unprecedented growth, market dominance and positioning Ozempic as an iconic brand

Strategic lead of core markets, and 15 senior marketeers Established company's cardiorenal market strategy
Product Launch Strategy Global Marketing New product launch Growth Strategies market expansion